Cantor Fitzgerald analyst Alethia Young raised her price target for Aurinia Pharmaceuticals to $30 from $24 citing the positive Phase 3 voclosporin trial data in lupus nephritis. She believes Aurinia has at least six years of exclusivity in the U.S. for voclosporin in lupus, but that the dosing patents may give longer protection for 10 years. Based on the Phase III Aurora study, Young estimates peak sales of ~$2B for voclosprorin in lupus nephritis. The stock "may continue to trade up from here," says the analyst, who keeps an Overweight rating on the shares. Aurinia Pharmaceuticals is up 93%, or $7.79, to $16.18 in midday trading.